NDAINTRAVENOUSEMULSION
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
8/8 — Comprehensive
CINVANTI (aprepitant) by Heron Therapeutics is neurokinin 1 antagonists [moa]. Approved for chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting. First approved in 2017.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CINVANTI (aprepitant) is an intravenous neurokinin-1 receptor antagonist approved in 2017 for chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting, and multiple cancer indications. It works by blocking substance P signaling in the brain's chemoreceptor trigger zone, preventing nausea and vomiting in patients undergoing highly emetogenic chemotherapy or surgery.
$0.142MPart D
Peak9.4 years to LOECINVANTI is at peak commercial maturity with minimal Part D penetration, suggesting a focused, specialized sales team in oncology and perioperative settings rather than broad commercial expansion.
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Worked on CINVANTI at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.